The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

After Reuters reported that CVS Health (CVS) will not cover Gilead’s (GILD) Yeztugo for HIV PrEP therapy in their commercial and ACA plans, ...

CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports.

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Shares in biopharmaceutical group Gilead Sciences ($GILD) dropped 1% today after pharmacy firm CVS Health ($CVS) gave the ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health, which operates the largest U.S. pharmacy benefit ... The decision was based on clinical, financial, and regulatory factors, according to a Reuters report. The company added that its ACA ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the federal False Claims Act.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...